Chronic Kidney Disease
📧 Sign up to get email alerts when something new happens for Chronic Kidney Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-10-26FDA Approved: FARXIGA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for Farxiga (dapagliflozin) from AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2018-10-25FDA Approved: SEVELAMER CARBONATE FOR ORAL SUSPENSION — Original Application (Dr. Reddys Laboratories Inc)
FDA approved an original ANDA for Sevelamer carbonate for oral suspension from Dr. Reddy's Laboratories Inc.
-
CLINICAL_TRIALS trial_result · 2018-10-17Clinical Trial Update: Pilot Study of Velcade® in IgA Nephropathy [Phase 4]
Pilot Phase 4 study of Velcade in IgA nephropathy has completed with posted results.
-
FDA approval · 2018-10-11FDA Approved: CINACALCET — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved cinacalcet (Sun Pharmaceutical) via an original application; the generic CINACALCET is approved for secondary hyperparathyroidi…
-
CLINICAL_TRIALS trial_result · 2018-10-10Clinical Trial Update: Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria [Phase 3]
Phase 3 trial evaluating losartan for efficacy and safety in pediatric chronic kidney disease with tubular proteinuria has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia [Phase 3]
Phase III study of PA21 in hemodialysis patients with hyperphosphatemia has completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia [Phase 3]
Phase III trial update for PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia; study completed with results posted …
-
FDA approval · 2018-10-09FDA Approved: PARICALCITOL — Original Application (Eugia US LLC)
FDA approved the original ANDA for paricalcitol from Eugia US LLC, a vitamin D receptor activator, for the treatment of secondary hyperparat…
-
CLINICAL_TRIALS research · 2018-09-13Clinical Trial Update: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management [NA]
A completed clinical trial evaluating continuous glucose monitoring to guide glucose management in individuals with chronic kidney disease a…
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients [Phase 4]
Phase 4 clinical trial evaluating cholecalciferol supplementation for anemia and mineral and bone disorder in chronic kidney disease patient…
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [Phase 4]
Phase 4 trial update evaluating the prognostic value of circadian patterns in ambulatory blood pressure for risk assessment in hypertension …
-
CLINICAL_TRIALS trial_result · 2018-08-27Clinical Trial Update: Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients [Phase 4]
A Phase 4 clinical trial evaluated the effect of cholecalciferol supplementation on parathyroid hormone levels in hemodialysis patients with…
-
CLINICAL_TRIALS trial_result · 2018-08-24Clinical Trial Update: Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients [Phase 3]
Phase 3 clinical trial updating paricalcitol's effect on inflammatory parameters in patients with chronic kidney disease and completed statu…
-
CLINICAL_TRIALS trial_result · 2018-08-24Clinical Trial Update: A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration [Phase 2]
Phase 2 trial evaluating OPC-41061 in adults with chronic renal failure on dialysis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-08-21Clinical Trial Update: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) [Phase 3]
Phase 3 trial updating the efficacy and safety comparison between a calcineurin inhibitor (CNI) and a CNI-free regimen in renal transplantat…
-
CLINICAL_TRIALS trial_result · 2018-08-21Clinical Trial Update: Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula [NA]
A completed clinical trial evaluating phosphodiesterase type 5 inhibition to improve endothelial function and vascular remodeling in chronic…
-
FDA approval · 2018-08-20FDA Approved: PARSABIV — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for Parsabiv (etelcalcetide) from Amgen, updating the product labeling. The action relates to tr…
-
CLINICAL_TRIALS trial_result · 2018-08-20Clinical Trial Update: Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease. [Phase 3]
Phase 3 trial update evaluating the clinical efficacy of two erythropoietin drugs in participants with anemia secondary to chronic kidney di…
-
CLINICAL_TRIALS trial_result · 2018-08-15Clinical Trial Update: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) [Phase 4]
Phase 4 trial updating all-cause mortality and cardiovascular outcomes in CKD patients on dialysis or not, comparing Mircera to reference ES…
-
FDA approval · 2018-08-08FDA Approved: LASIX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for LASIX (furosemide) from Validus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2018-08-08Clinical Trial Update: Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [Phase 3]
Phase 3 trial assessing efficacy and safety of tolvaptan in adults with autosomal dominant polycystic kidney disease (late stage 2 to early …
-
CLINICAL_TRIALS trial_result · 2018-08-07Clinical Trial Update: The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4 [Phase 3]
Phase 3 trial evaluating the effect of sevelamer carbonate on serum TMAO levels in patients with chronic kidney disease stage 3b-4. Current …
-
CLINICAL_TRIALS trial_result · 2018-08-01Clinical Trial Update: Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D [Phase 3]
Phase 3 trial update for ferric citrate in transitioning from CKD stages 4/5 to 5D; study completed.
-
CLINICAL_TRIALS research · 2018-07-27Clinical Trial Update: Bedtime Potassium Losartan on CKD With Nocturnal Hypertension Patients With Nondipping Blood Pressure Pattern [NA]
A clinical trial update on bedtime dosing of losartan in patients with chronic kidney disease and nocturnal hypertension with nondipping blo…
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: The Role of Isolated Nocturnal Hypertension Pattern in Nondialysis CKD [NA]
This clinical trial update discusses the potential role of isolated nocturnal hypertension in nondialysis chronic kidney disease. The status…